ACTUALITES

SÉMINAIRES

ÉVÉNEMENTS

  • 2ème Symposium IRCI / 21-23 Juin 2020

La seconde édition du Symposium International IRCI (Immune Responses in Cancer and Infection) a été reportée à juin 2021 à l'Espaces Charles Mérieux, ENS Lyon.

Coorganisé par des chercheurs du Centre de Recherche en Cancérologie de Lyon et du Centre International de Recherche en Infectiologie, cet événement rassemblera la communauté scientifique intéressée par les dernières avancées dans le domaine de l’immunologie des cancers et des infections.

Le programme scientifique est axé autour de 6 sessions thématiques et des interventions de 20 conférenciers invités de renommée internationale tels que le Pr. Harald Zur Hausen (DKFZ, Allemagne), Prix Nobel de Médecine 2008 et le Pr. Ruslan Medzhitov (Yale University, Etats-Unis).

Pour plus d'informations, rendez-vous sur : https://irci2021.insight-outside.fr/

DIVERS

DERNIÈRES PUBLICATIONS

  • Ancient and conserved functional interplay between Bcl-2 family proteins in the mitochondrial pathwa

In metazoans, Bcl-2 family proteins are major regulators of mitochondrially mediated apoptosis; however, their evolution remains poorly understood. Here, we describe the molecular characterization of the four members of the Bcl-2 family in the most primitive metazoan, Trichoplax adhaerens All four trBcl-2 homologs are multimotif Bcl-2 group, with trBcl-2L1 and trBcl-2L2 being highly divergent antiapoptotic Bcl-2 members, whereas trBcl-2L3 and trBcl-2L4 are homologs of proapoptotic Bax and Bak, respectively. trBax expression permeabilizes the mitochondrial outer membrane, while trBak operates as a BH3-only sensitizer repressing antiapoptotic activities of trBcl-2L1 and trBcl-2L2. The crystal structure of a trBcl-2L2:trBak BH3 complex reveals that trBcl-2L2 uses the canonical Bcl-2 ligand binding groove to sequester trBak BH3, indicating that the structural basis for apoptosis control is conserved from T. adhaerens to mammals. Finally, we demonstrate that both trBax and trBak BH3 peptides bind selectively to human Bcl-2 homologs to sensitize cancer cells to chemotherapy treatment.
DOI:10.1126/sciadv.abc4149

  • Failed Apoptosis Enhances Melanoma Cancer CellAggressiveness

Triggering apoptosis remains an efficient strategy to treat cancer. However, apoptosis is no longer a final destination since cancer cells can undergo failed apoptosis without dying. Recent evidence shows that limited mitochondrial permeabilization and non-lethal caspase activation occur under certain circumstances, although it remains unclear how failed apoptosis affects cancer cells. Using an original cancer cell model to trigger non-lethal caspase activation, we find that melanoma cancer cells undergoing failed apoptosis have a particular transcriptomic signature associated with focal adhesions, transendothelial migration, and modifications of the actin cytoskeleton. In line with this, cancer cells surviving apoptosis gain migration and invasion properties in vitro and in vivo. We further demonstrate that failed apoptosis-associated gain in invasiveness is regulated by the c-Jun N-terminal kinase (JNK) pathway, whereas its RNA sequencing signature is found in metastatic melanoma. These findings advance our understanding of how cell death can both cure and promote cancer. 

OFFRES D'EMPLOI

  • November 2020 - Post-doctoral position

PostDoc Position in single cell OMICS applied to immune-oncology.
The "Tumor immune surveillance and therapeutic targeting" team, headed by Christophe Caux, is looking for a motivated Postdoctoral researcher to work at the forefront of single cell and oncology research in q stimulating environment interfacing academic and private sectors. The candidate will bridge the gap between fundamental research in the field of cancer biology and market-oriented development of single cell OMICS by working between the Cancer Research Center of Lyon (CRCL) at the Centre Léon Bérard and Cellenion SASU
More information

  • November 2020 - postdoctoral position

A postdoctoral position is available in the "Stemness in gliomas" team headed by François Ducray, MD-PhD, and Mathieu gabut, PhD.
More information

  • October 2020 - Post-doctoral position

A post-doctoral position is available in the laboratory of Dr. Julien Ablain. The Ablain lab studies cancer biology, focusing on the role of adhesion signaling in melanoma metastasis.
More information

  • October 2020 - Post-doctoral position

A postdoctoral position is available at the CRCL - INSERM U1052 CNRS UMR5286 in the research team of Dr Virginie Petrilli to work on the characterization of the regulation of the ATM pathway by the Pattern Recognition Receptor NLRP3.
More information

  • September 2020 - Lab manager position

L'équipe "TGF-beta et régulation de la réponse immunitaire", Dirigée par Julien Marie, recherche un lab manager.  L’équipe est composée de 12 personnes et étudie principalement les effets du système immunitaire sur les cancers.
Consulter l'offre.

  • September 2020 - Research Engineer position

A research engineer position in bioinformatics is open to work on an innovative joint research program between two teams of CRCL and Bioinformatics Center in Lyon, France.
More Information

  • September 2020 - Project manager in immunology

The Laboratory of Immunotherapy of Cancer of Lyon (LICL) is currently seeking a talented and experienced immunologist to coordinate the scientific and technological projects within the lab.
The LICL (head: C. Caux) is affiliated to the Cancer Research Center of Lyon (CRCL) and to the department of Translational Research and Innovation of the comprehensive Léon Bérard cancer Center (CLB) at the interface between fundamental research developed within the CRCL immunology teams and the clinical research implemented by the CLB clinical teams.
More information

  • July 2020 - Postdoctoral position

The laboratory of Prof Julien C. Marie is seeking an experienced, creative and autonomous post-doctoral fellow to study the effects of TGF-b on T cell-biology. A particular focus is proposed on deciphering mechanisms of action of TGF-b in controlling skin inflammation using both in vitro and in vivo mouse models.
More Information

  • January 2020 - Post-doctoral position

The laboratory of Dr. Julien C. Marie is seeking an experienced, creative and autonomous post-doctoral fellow to study the effects of TGF-B on T cell-biology.
More information

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :